Atgam

Atgam

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Lymphocyte Ig, anti-thymocyte globulin (equine)
Indications/Uses
Moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation. Management of allograft rejection in renal transplant patients. Adjunct to other immunosuppressive therapy to delay onset of 1st rejection episode.
Dosage/Direction for Use
Aplastic anaemia 10-20 mg/kg IV daily for 8-14 days. Additional alternate day therapy up to total of 21 doses can be given. Renal transplant rejection 10-15 mg/kg IV daily for 14 days. Additional alternate day therapy up to total of 21 doses can be given. Delaying onset of allograft rejection 15 mg/kg daily for 14 days, then every other day for 14 days up to 21 doses in 28 days. 1st dose to be given w/in 24 hr before or after transplant.
Contraindications
Hypersensitivity to lymphocyte Ig, anti-thymocyte globulin (equine), other equine γ globulin prep or after previous inj.
Special Precautions
Discontinue use if anaphylaxis occurs. Monitor patients for concurrent infection. Perform skin testing prior to treatment. Monitor hepatic & renal function. Not to be used w/ live vaccines. Pregnancy & lactation. Elderly ≥65 yr.
Adverse Reactions
Pyrexia, chills, rash, thrombocytopenia, leukopenia, arthralgia.
Drug Interactions
Previously masked reactions may reappear w/ reduced dose of corticosteroids & other immunosuppressants.
MIMS Class
Immunosuppressants
ATC Classification
J06BA02 - immunoglobulins, normal human, for intravascular adm. ; Belongs to the class of normal human immunoglobulins. Used in passive immunizations.
Presentation/Packing
Form
Atgam inj (amp) 50 mg/mL
Packing/Price
5 mL x 5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in